These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10088136)

  • 1. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease.
    Riekkinen P; Riekkinen M
    Neuropsychopharmacology; 1999 Apr; 20(4):357-64. PubMed ID: 10088136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease.
    Riekkinen M; Riekkinen P
    J Clin Psychopharmacol; 1999 Oct; 19(5):444-9. PubMed ID: 10505586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guanfacine, but not clonidine, improves planning and working memory performance in humans.
    Jäkälä P; Riekkinen M; Sirviö J; Koivisto E; Kejonen K; Vanhanen M; Riekkinen P
    Neuropsychopharmacology; 1999 May; 20(5):460-70. PubMed ID: 10192826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease.
    Riekkinen M; Soininen H; Riekkinen P; Kuikka J; Laakso M; Helkala EL; Partanen J; Riekkinen P
    Neuroscience; 1998 Mar; 83(2):471-9. PubMed ID: 9460755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
    Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
    N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrine treatment of Alzheimer's disease: many expectations, few certainties.
    Malaguarnera M; Pistone G; Vinci M; Motta M; di Fazio I; Rampello L
    Neuropsychobiology; 1998 Nov; 38(4):226-31. PubMed ID: 9813462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility.
    Choi Y; Novak JC; Hillier A; Votolato NA; Beversdorf DQ
    Cogn Behav Neurol; 2006 Dec; 19(4):204-7. PubMed ID: 17159617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of Tacrine and the measurement of outcomes of Alzheimer's disease.
    Int J Technol Assess Health Care; 1998; 14(2):398-9. PubMed ID: 9678977
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease.
    Perryman KM; Fitten LJ
    Life Sci; 1993; 53(6):479-86. PubMed ID: 8341134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans.
    Jäkälä P; Sirviö J; Riekkinen M; Koivisto E; Kejonen K; Vanhanen M; Riekkinen P
    Neuropsychopharmacology; 1999 Feb; 20(2):119-30. PubMed ID: 9885792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cholinesterase inhibitors on attention.
    Pepeu G; Giovannini MG; Bracco L
    Chem Biol Interact; 2013 Mar; 203(1):361-4. PubMed ID: 23047023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrine: a second look. An outdated drug to be discarded.
    Prescrire Int; 1999 Feb; 8(39):16-8. PubMed ID: 10557569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease.
    Lebert F; Mouly C; Pasquier F
    Age Ageing; 1998 Sep; 27(5):654. PubMed ID: 12675108
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study.
    Fitten LJ; Perryman KM; Gross PL; Fine H; Cummins J; Marshall C
    Am J Psychiatry; 1990 Feb; 147(2):239-42. PubMed ID: 2405720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.